{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:56:01Z","timestamp":1790560561389,"version":"4.1.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T00:00:00Z","timestamp":1783123200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T00:00:00Z","timestamp":1790553600000},"content-version":"vor","delay-in-days":86,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Gastroenterol"],"DOI":"10.1186\/s12876-026-05075-y","type":"journal-article","created":{"date-parts":[[2026,7,4]],"date-time":"2026-07-04T01:34:18Z","timestamp":1783128858000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Determinants of eligibility for second-line chemotherapy following gemcitabine plus nab-paclitaxel therapy in patients with unresectable pancreatic cancer: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Tsuyoshi","family":"Ueda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichiro","family":"Miyagawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michihiko","family":"Shibata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuhisa","family":"Mori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinji","family":"Oe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenta","family":"Kajitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Uchihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuhiko","family":"Shinohara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriyoshi","family":"Ogino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinsuke","family":"Kumei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuichi","family":"Honma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuyuki","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masaru","family":"Harada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,4]]},"reference":[{"issue":"1","key":"5075_CR1","first-page":"17","volume":"73","author":"RL Siegel","year":"2023","unstructured":"Siegel RL, Miller KD, Wagle NS, Jemal A. Cancer statistics, 2023. CA Cancer J Clin. 2023;73(1):17\u201348.","journal-title":"CA Cancer J Clin"},{"key":"5075_CR2","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program. SEER*Stat Incidence\u2014SEER Research Data, 17 Registries, Nov 2022 Sub (2000\u20132020) - Linked To County Attributes\u2014Time Dependent (1990\u20132021) Income\/Rurality, 1969\u20132021 Counties. National Cancer Institute, Division of Cancer Control and Population Sciences, Surveillance Research Program; 2023."},{"issue":"3","key":"5075_CR3","first-page":"229","volume":"74","author":"F Bray","year":"2022","unstructured":"Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"5075_CR4","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1097\/MPA.0000000000001513","volume":"49","author":"T Okusaka","year":"2019","unstructured":"Okusaka T, Nakamura M, Yoshida M, Kitano M, Uesaka K, Ito Y, et al. Clinical practice guidelines for pancreatic cancer 2019 from the Japan Pancreas Society: a synopsis. Pancreas. 2019;49(3):326\u201335.","journal-title":"Pancreas"},{"issue":"11","key":"5075_CR5","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1016\/j.ejca.2011.04.011","volume":"47","author":"U Pelzer","year":"2011","unstructured":"Pelzer U, Schwaner I, Stieler J, Adler M, Seraphin J, D\u00f6rken B, et al. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group. Eur J Cancer. 2011;47(11):1676\u201381.","journal-title":"Eur J Cancer"},{"issue":"1","key":"5075_CR6","doi-asserted-by":"publisher","first-page":"19399","DOI":"10.1038\/s41598-023-46924-0","volume":"13","author":"M Fukahori","year":"2023","unstructured":"Fukahori M, Okabe Y, Shimokawa M, Otsuka T, Koga F, Ueda Y, et al. Efficacy of second-line chemotherapy after treatment with gemcitabine plus nab-paclitaxel or FOLFIRINOX in patients with metastatic pancreatic cancer. Sci Rep. 2023;13(1):19399.","journal-title":"Sci Rep"},{"issue":"9","key":"5075_CR7","first-page":"799","volume":"21","author":"Y Liu","year":"2024","unstructured":"Liu Y, Guo X, Xu P, Song Y, Huang J, Chen X, et al. Clinical outcomes of second-line chemotherapy in patients with advanced pancreatic adenocarcinoma: a real-world study. Cancer Biol Med. 2024;21(9):799\u2013812.","journal-title":"Cancer Biol Med"},{"issue":"12","key":"5075_CR8","doi-asserted-by":"publisher","first-page":"5433","DOI":"10.1007\/s12325-022-02317-9","volume":"39","author":"G King","year":"2022","unstructured":"King G, Ittershagen S, He L, Shen Y, Li F, Villacorta R. Treatment patterns in US patients receiving first-line and second-line therapy for metastatic pancreatic ductal adenocarcinoma in the real world. Adv Ther. 2022;39(12):5433\u201352.","journal-title":"Adv Ther"},{"key":"5075_CR9","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/s12885-024-13386-0","volume":"25","author":"M Aseafan","year":"2025","unstructured":"Aseafan M, Alfakeeh AH, Tashkandi E, Mahrous M, Alghamdi M, Alshamsan B, et al. Real-world clinical outcome of unresectable locally advanced and de-novo metastatic pancreatic ductal adenocarcinoma: a multicentre retrospective study. BMC Cancer. 2025;25:7.","journal-title":"BMC Cancer"},{"issue":"4","key":"5075_CR10","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1097\/MPA.0000000000000533","volume":"45","author":"M Sinn","year":"2016","unstructured":"Sinn M, D\u00e4lken L, Striefler JK, Bischoff S, Schweitzer N, Pelzer U, et al. Second-line treatment in pancreatic cancer patients: who profits? Results from the CONKO Study Group. Pancreas. 2016;45(4):601\u20135.","journal-title":"Pancreas"},{"key":"5075_CR11","doi-asserted-by":"publisher","unstructured":"Vienot A, Beinse G, Louvet C, de Mestier L, Meurisse A, Fein F, et al. Overall survival prediction and usefulness of second-line chemotherapy in advanced pancreatic adenocarcinoma. J Natl Cancer Inst. 2017;109(10): https:\/\/doi.org\/10.1093\/jnci\/djx037.","DOI":"10.1093\/jnci\/djx037"},{"issue":"12","key":"5075_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.7345","volume":"13","author":"G Giordano","year":"2024","unstructured":"Giordano G, Milella M, Landriscina M, Bergamo F, Tirino G, Santaniello A, et al. Prognostic analysis and outcomes of metastatic pancreatic cancer patients receiving nab-paclitaxel plus gemcitabine as second or later-line treatment. Cancer Med. 2024;13(12):e7345.","journal-title":"Cancer Med"},{"issue":"51","key":"5075_CR13","doi-asserted-by":"publisher","first-page":"88835","DOI":"10.18632\/oncotarget.21340","volume":"8","author":"Y Gao","year":"2017","unstructured":"Gao Y, Wang WJ, Zhi Q, Shen M, Jiang M, Bian X, et al. Neutrophil\/lymphocyte ratio is a more sensitive systemic inflammatory response biomarker than platelet\/lymphocyte ratio in the prognosis evaluation of unresectable pancreatic cancer. Oncotarget. 2017;8(51):88835\u201344.","journal-title":"Oncotarget"},{"issue":"3","key":"5075_CR14","first-page":"223","volume":"12","author":"DC McMillan","year":"2009","unstructured":"McMillan DC. Systemic inflammation, nutritional status and survival in patients with cancer. Curr Opin Clin Nutr Metab Care. 2009;12(3):223\u20136.","journal-title":"Curr Opin Clin Nutr Metab Care"},{"issue":"1","key":"5075_CR15","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1016\/j.pan.2017.11.011","volume":"18","author":"S Isaji","year":"2018","unstructured":"Isaji S, Mizuno S, Windsor JA, Bassi C, Fern\u00e1ndez-Del Castillo C, Hackert T, et al. International consensus on definition and criteria of borderline resectable pancreatic ductal adenocarcinoma 2017. Pancreatology. 2018;18(1):2\u201311.","journal-title":"Pancreatology"},{"issue":"6","key":"5075_CR16","doi-asserted-by":"publisher","first-page":"977","DOI":"10.1016\/j.surg.2014.02.001","volume":"155","author":"M Bockhorn","year":"2014","unstructured":"Bockhorn M, Uzunoglu FG, Adham M, Imrie C, Milicevic M, Sandberg AA, et al. Borderline resectable pancreatic cancer: a consensus statement by the International Study Group of Pancreatic Surgery (ISGPS). Surgery. 2014;155(6):977\u201388.","journal-title":"Surgery"},{"issue":"2","key":"5075_CR17","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45(2):228\u201347.","journal-title":"Eur J Cancer"},{"issue":"11","key":"5075_CR18","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1002\/jhbp.12056","volume":"31","author":"M Ishida","year":"2024","unstructured":"Ishida M, Fujii T, Kishiwada M, Shibuya K, Satoi S, Ueno M, et al. Japanese classification of pancreatic carcinoma by the Japan Pancreas Society: eighth edition. J Hepatobiliary Pancreat Sci. 2024;31(11):755\u201368.","journal-title":"J Hepatobiliary Pancreat Sci"},{"issue":"1","key":"5075_CR19","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3892\/etm.2010.175","volume":"2","author":"Y Toiyama","year":"2011","unstructured":"Toiyama Y, Miki C, Inoue Y, Tanaka K, Mohri Y, Kusunoki M. Evaluation of an inflammation-based prognostic score for the identification of patients requiring postoperative adjuvant chemotherapy for stage II colorectal cancer. Exp Ther Med. 2011;2(1):95\u2013101.","journal-title":"Exp Ther Med"},{"issue":"4","key":"5075_CR20","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1093\/ajcn\/82.4.777","volume":"82","author":"O Bouillanne","year":"2005","unstructured":"Bouillanne O, Morineau G, Dupont C, Coulombel I, Vincent JP, Nicolis I, et al. Geriatric Nutritional Risk Index: a new index for evaluating at-risk elderly medical patients. Am J Clin Nutr. 2005;82(4):777\u201383.","journal-title":"Am J Clin Nutr"},{"issue":"11","key":"5075_CR21","doi-asserted-by":"publisher","first-page":"1508","DOI":"10.1016\/j.ejso.2015.07.022","volume":"41","author":"Y Geng","year":"2015","unstructured":"Geng Y, Qi Q, Sun M, Chen H, Wang P, Chen Z. Prognostic nutritional index predicts survival and correlates with systemic inflammatory response in advanced pancreatic cancer. Eur J Surg Oncol. 2015;41(11):1508\u201314.","journal-title":"Eur J Surg Oncol"},{"issue":"3","key":"5075_CR22","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1080\/01635581.2016.1250921","volume":"69","author":"SH Lee","year":"2017","unstructured":"Lee SH, Chung MJ, Kim B, Lee HS, Lee HJ, Heo JY, et al. The significance of the prognostic nutritional index for all stages of pancreatic cancer. Nutr Cancer. 2017;69(3):512\u20139.","journal-title":"Nutr Cancer"},{"key":"5075_CR23","unstructured":"National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): National Cancer Institute; 2017. Available from:\u00a0https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/ctc.htm.\u00a0Cited 2024 Dec 31."},{"key":"5075_CR24","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1111\/ajco.13598","volume":"18","author":"G Colloca","year":"2022","unstructured":"Colloca G. Performance status as prognostic factor in phase III trials of first-line chemotherapy of unresectable or metastatic pancreatic cancer: a trial-level meta-analysis. Asia Pac J Clin Oncol. 2022;18:232\u20139.","journal-title":"Asia Pac J Clin Oncol"},{"issue":"3","key":"5075_CR25","doi-asserted-by":"publisher","first-page":"155932582094206","DOI":"10.1177\/1559325820942065","volume":"18","author":"W Fu","year":"2020","unstructured":"Fu W, Wang K, Yan S, Wang X, Tang B, Chang J, et al. Prognostic significance of the modified Glasgow Prognostic Score in patients with pancreatic cancer: a meta-analysis. Dose Response. 2020;18(3):1559325820942065.","journal-title":"Dose Response"},{"issue":"6","key":"5075_CR26","doi-asserted-by":"publisher","first-page":"982","DOI":"10.21037\/jgo.2016.06.06","volume":"7","author":"M Kadokura","year":"2016","unstructured":"Kadokura M, Ishida Y, Tatsumi A, Takahashi E, Shindo H, Amemiya F, et al. Performance status and neutrophil-lymphocyte ratio are important prognostic factors in elderly patients with unresectable pancreatic cancer. J Gastrointest Oncol. 2016;7(6):982\u20138.","journal-title":"J Gastrointest Oncol"},{"issue":"18","key":"5075_CR27","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369(18):1691\u2013703.","journal-title":"N Engl J Med"},{"key":"5075_CR28","doi-asserted-by":"crossref","unstructured":"Ohba A, Ozaka M, Mizusawa J, Okusaka T, Kobayashi S, Yamashita T, et al; Hepatobiliary and Pancreatic Oncology Group of the Japan Clinical Oncology Group (JCOG-HBPOG). Modified fluorouracil, leucovorin, irinotecan, and oxaliplatin or S-1, irinotecan, and oxaliplatin versus nab-paclitaxel plus gemcitabine in metastatic or recurrent pancreatic cancer (GENERATE, JCOG1611): a randomized, open-label, phase II\/III trial. J Clin Oncol. 2025;43(31):3345\u201354.","DOI":"10.1200\/JCO.24.00936"},{"key":"5075_CR29","doi-asserted-by":"crossref","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al; NAPOLI-1 Study Group. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387(10018):545\u201357.","DOI":"10.1016\/S0140-6736(15)00986-1"},{"issue":"10","key":"5075_CR30","doi-asserted-by":"publisher","first-page":"4509","DOI":"10.21873\/anticanres.17798","volume":"45","author":"K Sato","year":"2025","unstructured":"Sato K, Suzuki R, Konno N, Irie H, Watanabe KO, Imaizumi H, et al. Development and validation of a nomogram to predict eligibility for second-line chemotherapy in pancreatic cancer. Anticancer Res. 2025;45(10):4509\u201318.","journal-title":"Anticancer Res"},{"issue":"10","key":"5075_CR31","doi-asserted-by":"publisher","first-page":"3477","DOI":"10.3390\/jcm12103477","volume":"12","author":"T Ikoma","year":"2023","unstructured":"Ikoma T, Matsumoto T, Boku S, Yasuda T, Masuda M, Ito T, et al. A retrospective study investigating the safety and efficacy of nanoliposomal irinotecan in elderly patients with unresectable pancreatic cancer. J Clin Med. 2023;12(10):3477.","journal-title":"J Clin Med"},{"issue":"2","key":"5075_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/j.lungcan.2004.07.040","volume":"47","author":"TA Hensing","year":"2005","unstructured":"Hensing TA, Schell MJ, Lee JH, Socinski MA. Factors associated with the likelihood of receiving second line therapy for advanced non-small cell lung cancer. Lung Cancer. 2005;47(2):253\u20139.","journal-title":"Lung Cancer"},{"key":"5075_CR33","doi-asserted-by":"crossref","unstructured":"Jang DK, Kim SJ, Chung HH, Lee JM, Yoon SB, Lee JC, et al. Korean Society of Gastrointestinal Cancer. Outcomes of Palliative Chemotherapy for Ampulla of Vater Adenocarcinoma: A Multicenter Cohort Study. Gut Liver. 2024;18(4):729-36.","DOI":"10.5009\/gnl230164"},{"issue":"10","key":"5075_CR34","doi-asserted-by":"publisher","first-page":"3522","DOI":"10.3390\/nu13103522","volume":"13","author":"G Rovesti","year":"2021","unstructured":"Rovesti G, Valoriani F, Rimini M, Bardasi C, Ballarin R, Di Benedetto F, et al. Clinical Implications of Malnutrition in the Management of Patients with Pancreatic Cancer: Introducing the Concept of the Nutritional Oncology Board. Nutrients. 2021;13(10):3522.","journal-title":"Nutrients"},{"issue":"5","key":"5075_CR35","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1016\/j.ccell.2026.03.012","volume":"44","author":"Y Zhang","year":"2026","unstructured":"Zhang Y, Nipp RD, Janowitz T, Li YP, Guttridge DC, Li M. Cancer cachexia: a tumor-driven disorder of whole-body homeostasis. Cancer Cell. 2026;44(5):913\u201332.","journal-title":"Cancer Cell"},{"issue":"6","key":"5075_CR36","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.102048","volume":"8","author":"JM Berger","year":"2023","unstructured":"Berger JM, Alany A, Berchtold L, Puhr R, Friedrich A, Scheiner B, et al. Prognosticators of survival in patients with metastatic pancreatic cancer and ascites. ESMO Open. 2023;8(6):102048.","journal-title":"ESMO Open"},{"issue":"2","key":"5075_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2023.101200","volume":"8","author":"JM Berger","year":"2023","unstructured":"Berger JM, Alany A, Puhr R, Berchtold L, Friedrich A, Scheiner B, et al. Clinical risk factors for ascites in metastatic pancreatic cancer. ESMO Open. 2023;8(2):101200.","journal-title":"ESMO Open"},{"issue":"7","key":"5075_CR38","doi-asserted-by":"publisher","DOI":"10.14309\/ctg.0000000000000719","volume":"15","author":"J Wang","year":"2024","unstructured":"Wang J, Cui Y, Osipov A, Gong J, Pandol S, Lo S, et al. Ascites is a poor prognostic factor in advanced pancreatic adenocarcinoma and may be undertreated: a prospective cohort study. Clin Transl Gastroenterol. 2024;15(7):e00719.","journal-title":"Clin Transl Gastroenterol"}],"container-title":["BMC Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12876-026-05075-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12876-026-05075-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T01:16:05Z","timestamp":1790558165000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12876-026-05075-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,4]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["5075"],"URL":"https:\/\/doi.org\/10.1186\/s12876-026-05075-y","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-9285193\/v1","asserted-by":"object"}]},"ISSN":["1471-230X"],"issn-type":[{"value":"1471-230X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,4]]},"assertion":[{"value":"1 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of the University of Occupational and Environmental Health, Japan (approval no. UOEHCRB20-027).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The requirement for written informed consent was waived due to the retrospective design, and an opt-out consent procedure was implemented as approved by the Institutional Review Board of the University of Occupational and Environmental Health, Japan.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"584"}}